Applications of PET in Radiation Oncology
1139Introduction: Thoracic malignancies are among the most common malignancies diagnosed both in the United States and worldwide. Radiation therapy (RT) plays an important role in the treatment of thoracic malignancies. Depending on the primary disease site and tumor stage, RT can be used as monotherapy, or as part of multimodality therapy for curative intent, or for palliative reduction of advanced disease. In fact, more than 50% of all patients with thoracic malignancies will receive RT as part of their multidisciplinary care. 18F-Fluorodeoxyglucose positron emission tomography (PET) is commonly used for initial cancer diagnosis, disease staging, outcome prognostication, radiation therapy (RT) planning, treatment response assessment, and detection of recurrent disease. In radiation oncology, PET plays a major role in RT target volume delineation, treatment response monitoring, evaluation for radiation-induced toxicities, and verification of radiation dose delivery. As advanced techniques such as intensity-modulated radiation therapy (IMRT) and proton therapy have increased in utilization, positron emission tomography/computed tomography (PET/CT) have played increasingly critical roles in the target delineation of tumors for radiation oncologists delivering conformal treatments, especially when treating thoracic malignancies. In RT, improvement in target localization permits reduction of tumor contour margins, consequently reducing the volume of normal tissues irradiated. Fu...
In conclusion, the presence of anti-SOX1 abs alone is a potential predictor of an uncommon paraneoplastic neurological disorder, usually occurring in the setting of LEMS, PCD, and SCLC. The detection of anti-SOX1 abs contributes to an early diagnosis of underlying tumors, given the diversity of clinical symptoms and the absence of characteristic neuroimaging features. PMID: 33029958 [PubMed]
Publication date: Available online 9 October 2020Source: PhytomedicineAuthor(s): Jian-Shu Lou, Li-Ping Zhao, Zhi-Hui Huang, Xia-Yin Chen, Jing-Ting Xu, William Chi-Shing TAI, Karl W.K. Tsim, Yi-Tao Chen, Tian Xie
Publication date: Available online 9 October 2020Source: Cancer CellAuthor(s): Melinda A. Pruis, Burhan Hussain, Marleen Bakker, Rogier A.S. Hoek, Jelle R. Miedema, Anne-Marie C. Dingemans, Marthe S. Paats
Authors: Han AR, Lee S, Han S, Lee YJ, Kim JB, Seo EK, Jung CH Abstract Radiotherapy using ionizing radiation is a major therapeutic modality for advanced human lung cancers. However, ionizing radiation itself can induce malignant behaviors such as cancer cell migration and invasion, leading to local recurrence or distal metastasis. Therefore, safer and more effective agents that inhibit the metastatic behaviors of cancer cells in radiotherapy are needed. As a part of our ongoing search for new radiotherapy enhancers from medicinal herbs, we isolated the following triterpenoids from the ethanol extract of Centella ...
Publication date: Available online 8 October 2020Source: European Journal of RadiologyAuthor(s): Tao Yu
Publication date: December 2020Source: Cancer Epidemiology, Volume 69Author(s): Chun-Pin Chang, Travis J. Meyers, Alan Fu, Ming-Yan Zhang, Donald P. Tashkin, Jian-Yu Rao, Wendy Cozen, Thomas M. Mack, Mia Hashibe, Hal Morgenstern, Zuo-Feng Zhang
Abstract Intracavitary cardiac metastasis is a rare manifestation of primary lung cancer which can be associated with a very poor prognosis. In this condition, the right chambers of the heart are more commonly involved and the invasion of the left atrium (LA) through the venous routes is highly exceptional. Poorly differentiated large-cell neuroendocrine tumors also include only 3% of all primary lung carcinomas which can have adverse outcomes. Therefore, in this report, a rare case of a 72-year-old male patient with poorly differentiated large-cell neuroendocrine carcinoma of the right lung spreading to the LA th...
Publication date: Available online 8 October 2020Source: The Annals of Thoracic SurgeryAuthor(s): Gail E. Darling, Martin C. Tammemägi, Heidi Schmidt, Daniel N. Buchanan, Yvonne Leung, Caitlin McGarry, Linda Rabeneck
Publication date: Available online 8 October 2020Source: The Annals of Thoracic SurgeryAuthor(s): Jean-Baptiste Leclère, Ludovic Fournel, Harry Etienne, Charbel Al Zreibi, Ilaria Onorati, Arnaud Roussel, Yves Castier, Emmanuel Martinod, Françoise Le Pimpec-Barthes, Marco Alifano, Jalal Assouad, Pierre Mordant, thoracic surgery units of Paris Public Hospitals.
Conclusion: This investigation provides a unique perspective into the biological growth of metastatic brain lesions. It is our hope that this study guides timing of treatment and informs both clinicians and patients of tumor growth kinetics before initiating treatment for intracranial metastases. PMID: 33024592 [PubMed]